IceCure Medical Showcases Innovations at SBI 2026 Symposium Amid Strong Revenue Growth

IceCure Medical Ltd., a prominent developer of cryoablation technology, is making waves in the medical community with its notable participation in the Society of Breast Imaging (SBI) Symposium held in Seattle from April 16-19, 2026. The company has recently announced a significant revenue boost, with earnings from its ProSense® systems and cryoprobes surging by over 30% in the first quarter of 2026 compared to the same period last year. These preliminary financial figures reflect the growing acceptance and demand for their innovative technology in the fight against breast cancer.

Following the FDA's clearance for the ProSense® system specifically aimed at women aged 70 and above with low-risk breast cancer in October 2025, IceCure has seen a heightened interest from healthcare providers. The presentation at the SBI Symposium was strategically timed, showcasing IceCure's commitment to educating healthcare professionals about the advantages of cryoablation as a treatment modality. The highlight of their exhibition included hands-on training workshops, allowing physicians to better understand the practical applications of ProSense® technology.

A pivotal moment at the conference was the presentation of an award-winning abstract entitled "Cost Analysis of Percutaneous Cryoablation versus Breast Conserving Surgery for the Treatment of Breast Cancer: Implications for Cost Efficacy-based Treatment Strategy." Presented by Dr. Matt Hoyer from Massachusetts General Hospital, this study received the Wendell Scott Research Award for being the most outstanding abstract. It revealed that utilizing cryoablation could potentially reduce overall treatment costs by more than 50% when compared to traditional lumpectomy procedures, highlighting its viability for low-risk early-stage breast cancer patients. The abstract not only emphasized the economic advantages of cryoablation but also aligned with emerging trends in value-based healthcare.

During a dedicated workshop titled "How I Do It – Cryoablation Working It Up and Freezing it Out," renowned medical experts Dr. Luz A. Venta and Dr. Robert C. Ward provided invaluable insights into the clinical integration of cryoablation. Their discussions focused on refining diagnostic imaging procedures prior to treatment and outlining the key procedural techniques necessary for effective application. The interactive element of the workshop, featuring live Q&A sessions, encouraged participants to engage directly with the experts, thus deepening their understanding of the benefits and implementation strategies for cryoablation.

CEO Eyal Shamir expressed confidence in the shifting landscape of breast cancer treatment, asserting that the increasing popularity of cryoablation reflects a meaningful transition in clinical approaches. He pointed out that IceCure's ongoing expansion of the ProSense® systems in leading academic and research hospitals underscores the growing trust in this innovative treatment. Furthermore, the company is optimistic about closing new sales in the second quarter of 2026, driven by robust interest from prospective customers.

Looking ahead, IceCure Medical plans to release its full financial results for Q1 2026 on May 14, 2026. Stakeholders and interested parties can expect further details on the company's performance during this anticipated update. Notably, the impressive performance indicators are further supported by ICE3 trial outcomes, which emphasize the safety and effectiveness of cryoablation as a treatment strategy.

ProSense® Cryoablation technology represents a groundbreaking advancement in non-invasive tumor treatment, utilizing liquid nitrogen to freeze and obliterate tumors without surgical intervention. This method not only speeds recovery times and minimizes pain but also reduces overall surgical risks and complications. Positioned to become a standard care option, ProSense® is tailored to meet the needs of patients who require effective treatment options without the traditional burdens associated with surgery.

IceCure Medical continues to position itself at the forefront of cancer treatment innovation, blending advanced technology with patient-centered care. With a robust pipeline for future developments and an ever-growing base of medical professionals adopting cryoablation techniques, the future looks promising for IceCure and its commitment to revolutionizing cancer treatment.

In summary, IceCure Medical's active role at SBI 2026 not only showcases their commitment to enhancing breast cancer treatment methodologies but also reflects a broader trend toward cost-effective, patient-friendly surgical alternatives. As healthcare evolves, IceCure's innovations are set to play a crucial role in shaping the future of oncological care.